Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Purpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study include...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557000688762880 |
|---|---|
| author | Carlo A. Vignoli Luigi Gargiulo Luciano Ibba Anna Balato Mauro Barbareschi Stefania Barruscotti Giulia Bazzacco Francesco Bellinato Vittoria G. Bianchi Valeria Boccaletti Raffaele D. Caposiena Caro Silvia M. Ferrucci Alessandro Fraghì Elisabetta Fulgione Giuseppe Gallo Paolo Gisondi Isotta Giunipero di Corteranzo Piergiorgio Malagoli Angelo V. Marzano Santo R. Mercuri Diego Orsini Pietro Quaglino Simone Ribero Antonio Costanzo Alessandra Narcisi |
| author_facet | Carlo A. Vignoli Luigi Gargiulo Luciano Ibba Anna Balato Mauro Barbareschi Stefania Barruscotti Giulia Bazzacco Francesco Bellinato Vittoria G. Bianchi Valeria Boccaletti Raffaele D. Caposiena Caro Silvia M. Ferrucci Alessandro Fraghì Elisabetta Fulgione Giuseppe Gallo Paolo Gisondi Isotta Giunipero di Corteranzo Piergiorgio Malagoli Angelo V. Marzano Santo R. Mercuri Diego Orsini Pietro Quaglino Simone Ribero Antonio Costanzo Alessandra Narcisi |
| author_sort | Carlo A. Vignoli |
| collection | DOAJ |
| description | Purpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units. All patients received 4 mg of baricitinib daily. Effectiveness was assessed using the Severity of Alopecia Tool (SALT) score, with the primary endpoint defined as achieving a SALT score ≤ 20 at week 52. Secondary endpoints included achieving a Clinician-Reported Outcome (ClinRO) score of 0 or 1 for eyebrow (ClinRO EB) and eyelash hair loss (ClinRO EL), with a ≥ 2-point improvement from baseline.Results: After 52 weeks, 61.5% of patients achieved a SALT score ≤ 20. Additionally, 67.6% and 69.7% of patients attained ClinRO EB and ClinRO EL scores of 0 or 1, respectively, with a ≥ 2-point improvement. No significant adverse safety events were reported during the study.Conclusions: The study confirms the long-term effectiveness and safety of baricitinib for severe AA in a real-world setting. These findings align with clinical trial results and reinforce baricitinib’s role as a viable treatment option for severe AA. |
| format | Article |
| id | doaj-art-377e50b7374746a184d312e9f2f57bc3 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-377e50b7374746a184d312e9f2f57bc32025-01-07T01:03:05ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2444494Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world studyCarlo A. Vignoli0Luigi Gargiulo1Luciano Ibba2Anna Balato3Mauro Barbareschi4Stefania Barruscotti5Giulia Bazzacco6Francesco Bellinato7Vittoria G. Bianchi8Valeria Boccaletti9Raffaele D. Caposiena Caro10Silvia M. Ferrucci11Alessandro Fraghì12Elisabetta Fulgione13Giuseppe Gallo14Paolo Gisondi15Isotta Giunipero di Corteranzo16Piergiorgio Malagoli17Angelo V. Marzano18Santo R. Mercuri19Diego Orsini20Pietro Quaglino21Simone Ribero22Antonio Costanzo23Alessandra Narcisi24Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyDermatology Clinic, Policlinico San Matteo IRCCS Foundation, Pavia, ItalyDermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalyUnit of Dermatology and Cosmetology, IRCCS San Raffaele Scientific Institute, Milan, ItalyDepartment of Medicine, Section of Dermatology, University of Brescia, Brescia, ItalyDermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Medicine, Section of Dermatology, University of Brescia, Brescia, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Section, Department of Medical Sciences, University of Turin, Turin, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, ItalyDermatology Section, Department of Medical Sciences, University of Turin, Turin, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyUnit of Dermatology and Cosmetology, IRCCS San Raffaele Scientific Institute, Milan, ItalyClinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, ItalyDermatology Section, Department of Medical Sciences, University of Turin, Turin, ItalyDermatology Section, Department of Medical Sciences, University of Turin, Turin, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyPurpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units. All patients received 4 mg of baricitinib daily. Effectiveness was assessed using the Severity of Alopecia Tool (SALT) score, with the primary endpoint defined as achieving a SALT score ≤ 20 at week 52. Secondary endpoints included achieving a Clinician-Reported Outcome (ClinRO) score of 0 or 1 for eyebrow (ClinRO EB) and eyelash hair loss (ClinRO EL), with a ≥ 2-point improvement from baseline.Results: After 52 weeks, 61.5% of patients achieved a SALT score ≤ 20. Additionally, 67.6% and 69.7% of patients attained ClinRO EB and ClinRO EL scores of 0 or 1, respectively, with a ≥ 2-point improvement. No significant adverse safety events were reported during the study.Conclusions: The study confirms the long-term effectiveness and safety of baricitinib for severe AA in a real-world setting. These findings align with clinical trial results and reinforce baricitinib’s role as a viable treatment option for severe AA.https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494Alopecia areatabaricitinibClinROJAK inhibitorsSALT |
| spellingShingle | Carlo A. Vignoli Luigi Gargiulo Luciano Ibba Anna Balato Mauro Barbareschi Stefania Barruscotti Giulia Bazzacco Francesco Bellinato Vittoria G. Bianchi Valeria Boccaletti Raffaele D. Caposiena Caro Silvia M. Ferrucci Alessandro Fraghì Elisabetta Fulgione Giuseppe Gallo Paolo Gisondi Isotta Giunipero di Corteranzo Piergiorgio Malagoli Angelo V. Marzano Santo R. Mercuri Diego Orsini Pietro Quaglino Simone Ribero Antonio Costanzo Alessandra Narcisi Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study Journal of Dermatological Treatment Alopecia areata baricitinib ClinRO JAK inhibitors SALT |
| title | Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study |
| title_full | Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study |
| title_fullStr | Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study |
| title_full_unstemmed | Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study |
| title_short | Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study |
| title_sort | baricitinib for the treatment of severe alopecia areata results from a 52 week multicenter retrospective real world study |
| topic | Alopecia areata baricitinib ClinRO JAK inhibitors SALT |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494 |
| work_keys_str_mv | AT carloavignoli baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT luigigargiulo baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT lucianoibba baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT annabalato baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT maurobarbareschi baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT stefaniabarruscotti baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT giuliabazzacco baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT francescobellinato baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT vittoriagbianchi baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT valeriaboccaletti baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT raffaeledcaposienacaro baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT silviamferrucci baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT alessandrofraghi baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT elisabettafulgione baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT giuseppegallo baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT paologisondi baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT isottagiuniperodicorteranzo baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT piergiorgiomalagoli baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT angelovmarzano baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT santormercuri baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT diegoorsini baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT pietroquaglino baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT simoneribero baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT antoniocostanzo baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy AT alessandranarcisi baricitinibforthetreatmentofseverealopeciaareataresultsfroma52weekmulticenterretrospectiverealworldstudy |